# Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

> **NCT05731752** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Hangzhou Hanx Biopharmaceuticals, Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HX009

## Key facts

- **NCT ID:** NCT05731752
- **Lead sponsor:** Hangzhou Hanx Biopharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-28
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05731752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05731752, "Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05731752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*